Study nepafenac 0.1% suspension in treating postoperative inflammation and ocular pain associated with surgery of cataract patients

Objective Build-study is to investigate the efficacy and safety of nepafenac ophthalmic suspension compared with the placebo group who had not used the drug in the treatment of postoperative inflammation and ocular pain in patients operated from cataracts. Method A randomized, placebo-controlled study. Patients using nepafenac, and in the placebo group were not taking any medication for that grupa.Terapijata is seen starting 1 day before cataract surgery and continued to the day of surgery and for the next 14 days. An additional drop also an applied one hour before surgery. Differences were evaluated in i14ot 7th postoperative day as the rate of inflammation through the presence or absence of ocular pain. Results The rate of cure 14ot postoperative day was 71.4% (75/105) in the group of nepafenac and 28.6% (30/105) in the kontrol group, indicating substantial rezliki in the cure rate between the two groups. Group Nepafenac demonstrate higher cure rates than the kontrol group, with a significant difference in the rate of recovery in the 7th and 14ot postoperative den.Stapkata the lack of ocular pain was 96.2% (102/106) in the nepafenac group and 67.6% (71 / 105) in the kontrol group, which here also shows significant differences between the groups. Conclusion Nepafenac ophthalmic suspension is a nonsteroidal anti inflammatory drug effective in the prevention of postoperative inflammation and ocular pain associated with cataract surgery